Biogen Inc., of Cambridge, Mass., entered a partnership for French diagnostic firm Theradiag SA to provide its Lisa Tracker kits for monitoring Flixabi, an infliximab biosimilar. Financial terms were not disclosed. Biogen has marketed Flixabi in France since 2016.